B-cell Lymphoma Clinical Trials in Salt Lake City, Utah
16 recruitingSalt Lake City, Utah
Showing 1–16 of 16 trials
Recruiting
Phase 2
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled36 locationsNCT05886036
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 3
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLymphoma, B-Cell+6 more
Lyell Immunopharma, Inc.400 enrolled38 locationsNCT07188558
Recruiting
Phase 1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled54 locationsNCT04609046
Recruiting
Phase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
Allogene Therapeutics250 enrolled73 locationsNCT06500273
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 2
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
Relapsed or Refractory Large B-cell Lymphoma
University of Utah29 enrolled1 locationNCT06788964
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting
Phase 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+12 more
AIDS Malignancy Consortium20 enrolled6 locationsNCT05077527
Recruiting
Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 2
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma+5 more
Aseel Alsouqi24 enrolled3 locationsNCT05873712
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+5 more
CRISPR Therapeutics AG120 enrolled7 locationsNCT05643742
Recruiting
Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
High-grade B-cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+3 more
SWOG Cancer Research Network227 enrolled104 locationsNCT05890352
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Non-Hodgkin LymphomaLymphomaLymphoma, Non-Hodgkin+4 more
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763
Recruiting
Phase 2
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Primary Mediastinal Large B Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United120 enrolled6 locationsNCT06238648